A university of chicago consortium phase II trial of SB-715992 in advanced renal cell cancer

作者：Lee Richard T; Beekman Kathleen E; Hussain Maha; Davis Nancy B; Clark Joseph I; Thomas Sachdev P; Nichols Katherine F; Stadler Walter M^*

来源：Clinical Genitourinary Cancer, 2008, 6(1): 21-24.

DOI：10.3816/CGC.2008.n.003

• kinesins
• Microtubules multidrug resistance-associated protein 2
• von Hippel-Lindau

Background: Advanced renal cell cancer (RCC) continues to have a. poor overall prognosis despite new FDA-approved therapies. Although taxane-based therapies are generally ineffective in RCC, research into the role of the von Hippel-Lindau protein has shown an association with microtubule dynamics. Mitotic kinesins are a class of molecular motors that also interact with microtubules and are required for proper mitotic function. SB-715992 is a new agent that inhibits the function of a mitotic kinesin known as kinesin spindle protein and leads to cell death. Patients and Methods: Twenty patients with previously treated advanced RCC were enrolled on this phase 11 trial of SB-715992, with response rate as a primary endpoint. Results: No patients responded with complete or partial remission. Six patients had stable disease, and 1 patient continues on therapy after 12 cycles. Common toxicities included anemia (80%) elevated, creatinine (70%) lymphopenia (45%) fatigue (50%) hyperglycermia,,, (50%), and dyspnea (45%). Reported grade 3/4 toxicities included dyspnea, fatigue, neutropenia with skin infection, dizziness, hyperuricemia, and hypertension. Conclusion: This dose and schedule of SB-715992 does not appear to have a significant cytotoxic effect for patients with previously treated advanced RCC.

• 出版日期2008-3